Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Mixture of hexa(sodium,lithium) 4-{[1,7-disulfonato-5-hydroxy-6-({4-[(6-methoxy-5-sulfonatobenzoheteromonocycle-2-yl)diazenyl]-5-alkyl-2-(3-sulfonatopropoxy)phenyl}diazenyl)naphthalen-2-yl]diazenyl}-5-hydroxy-1-(4-sulfonatophenyl)heteromonocycle-3-carboxylate and hexa(sodium,lithium) 4-{[1,7-disulfonato-5-hydroxy-6-({4-[(6-methoxy-7-sulfonatobenzoheteromonocycle-2-yl)diazenyl]-5-alkyl-2-(3-sulfonatopropoxy)phenyl}diazenyl)naphthalen-2-yl]diazenyl}-5-hydroxy-1-(4-sulfonatophenyl)heteromonocycle-3-carboxylate
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- december 2010-june 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study has been performed according to OECD guidelines and according to GLP principles.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 011
- Report date:
- 2011
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Details on test material:
- - Name of test material (as cited in study report): E-BK105
- Physical state: black colored powder
- Lot/batch No.: MB-1
- Expiration date of the lot/batch: five years from shipment (November 4, 2010)
- Stability under test conditions: the test substance was confirmed to be stable during the experimental period based on infrared absorption spectra
- Storage condition of test material: room temperature (permissible range 1°-30°C) in an air-tight container in a dark place
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc. (Hino Breeding Center)
- Age at study initiation: 6 weeks
- Weight at receipt (5 weeks old): 115.7 to 137.5 g for males and 93.1 to 115.2 g for females
- Housing: stainless-steel cages
- Diet: ad libitum autoclave-sterilized pellet diet (CRF-1, Oriental Yeast Co., Ltd)
- Water: ad libitum well water admixed with NaClO (about 2 ppm)
- Acclimation period: 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.4° to 23.9°C
- Humidity (%): 51.2 to 62.1%
- Air changes (per hr): 10 to 20 times
- Photoperiod (hrs dark / hrs light): 12h/12h
IN-LIFE DATES: From: January 18, 2011 To: March 1, 2011
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
Dosing solutions were prepared once every 6 or 7 days and stored in a cool place shielded from light. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Samples of the dosing solution at each concentration were analysed. Analytical method validation included linearity, repeatability, specificity, within-run precision and stability testing. All concentrations were within 100 ± 10% as the ratio to the nominal concentration; substance solutions were conformed to be stable after storage in a cool place and shielded from light for 8 days and following 6 hours at room temperature.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
50, 250, 1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 5; for the control and 1000 mg/kg bw groups an additional 5/sex for a 14 day recovery period
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on results obtained in "Seven days repeated dose toxicity study of E-BK105 in rats (No. P101032; dose levels 0, 100, 300 and 1000 mg/kg bw, with 5 rats/sex/dose). Low body weight gain or decreased body weight were noted on days 4 to 7 in 2 high dose males accompanied by low food intake. In addition, low values in the erythrocyte count and haematocrit and low values of potassium in females at and above 300 mg/kg bw/day, high MCHC values and low sodium values in high dose males and females, a high glucose value in high dose females, high adrenal weight and low seminal weight in high dose males. in addition, black feces were noted in males and females at and above 300 mg/kg bw/day. From these results the high dose level in the main study was set at 1000 mg/kg bw/day in which several toxicological changes were presumed to be induced, and subsequent doses were set at 250 and 50 mg/kg bw/day.
- Post-exposure recovery period in satellite groups: 14 days
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice a day during the dosing period; once a day during recovery period.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: once before dosing; once a week until week 6
BODY WEIGHT: Yes
- All animals were weighed on days 1, 8, 15, 22 and 28 during the dosing period and on days 29, 36 and 42 during the recovery period. The final body weight was also measured on the day of the scheduled necropsy.
FOOD CONSUMPTION:
- For all animals, gross weight of each feeder was weighed. Mean daily food consumption values during days 1 to 8, 8 to 15, 15 to 22, 22 to 27, 29 to 36 and 36 to 41 were calculated.
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at necropsy
- Anaesthetic used for blood collection: Yes, sodium pentobarbital (i.p., 30 mg/kg bw)
- Animals fasted: Yes, at least 18 hours
- How many animals: all animals at the scheduled necropsy
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: at necropsy
- Animals fasted: Yes, at least 18 hours
- How many animals: same as for haematology
URINALYSIS: Yes
- Time schedule for collection of urine: day 27
- Metabolism cages used for collection of urine: No, fresh urine samples excreted spontaneously on a washed tray under the cage were collected.
- Animals fasted: Yes
- Parameters checked: pH, protein, glucose, ketone body and occult blood were determined by means of reagent strip method.
NEUROBEHAVIOURAL EXAMINATION: Yes, FOB
- Time schedule for examinations: week 4
- Dose groups that were examined: all animals
- Battery of functions tested: sensory activity / grip strength / motor activity - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, according to guideline
HISTOPATHOLOGY: Yes, according to guideline - Statistics:
- Statistical analysis was performed with computer system, MiTOX-PPL with significant levels of 1% and 5% (two-tailed).
The group mean and standard deviation of the following items were calculated and homogeneity of the variance was tested by the Bartlett's test (significant level 5%) for grip strength, motor activity, body weights, food consumption, urinalysis, hematology, blood chemistry, absolute and relative organ weight. When the variance was homogeneous, the Dunnett's multiple comparison was applied, and when it was not homogeneous, the Steel's multiple comparison was applied to compare each test substance group to the control group.
For Histopathological examination, the grades were converted to numerical values, and the Mann-Whitney U test was applied to compare the control and each test substance group.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- from day 2 until 2 days after the final dosing black feces (test substance) were noted at 50 mg/kg bw/day (2m, 1f) and all rats in the higher dose groups
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- from day 2 until 2 days after the final dosing black feces (test substance) were noted at 50 mg/kg bw/day (2m, 1f) and all rats in the higher dose groups
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- in high dose females body weight was increased from day 22 onwards
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In high dose animals increased food consumption was observed on days 15 to 27 (males) and from day 8 in females
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- in high dose animals increased numbers (abs and rel) of reticulocytes (stat. sign in males)
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- by means of reagent strip method
- Behaviour (functional findings):
- no effects observed
- Description (incidence and severity):
- in FOB
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- High dose males showed an increased liver weight.
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- All animals showed black coloration of kidneys (and still present at the end of the recovery period in high dose rats (2m, 4f). In high dose animals black intestinal contents in the jejenum (1m), the ileum (2m, 2f) and the cecum (4m) were observed.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Squamous cell hyperplasia in(proventricular border) in mid dose (1m, 1f) and all high dose rats; increased globule leukocyte (glandular stomach) in high dose (4m, 3f). Hypertrophy of kidney distal tubular epithelium in mid (2m, 1f) and all high dose rats.
- Details on results:
- CLINICAL SIGNS: the staining of the feces is considered to be attributable to the color of the test substance.
HAEMATOLOGY: observed shorter PT and APTT values in high dose males are considered not toxicologically relevant. Slight differences in blood cell counts at the end of the recovery period were observed in high dose rats; in the absence of effects during the dosing period, these effects are not considered for risk assesment.
CLINICAL CHEMISTRY: In high dose females increase in total cholesterol was observed at the end of the recovery period. In the abseence of a similar effect during the dosing period, this effect is not considered for risk assessment.
ORGAN WEIGHTS: Observed increased thymus weight at the end of the recovery period is considered not relevant for risk assessment, as this effect was not observed at the end of the dosing period.
HISTOPATHOLOGY: NON-NEOPLASTIC
Squamous cell hyperplasia in stomach (proventricular border) in mid dose (1m, 1f) and all high dose rats; increased globule leukocyte (glandular stomach) in high dose (4m, 3f). Hypertrophy of kidney distal tubular epithelium in mid (2m, 1f) and all high dose rats and hypertrophy of the kidney collecting duct in mid (1m) and high dose (5m, 4f) rats.
At the end of the recovery period, in high dose rats slight hypertrophy of the collecting duct epithelium was noted (4m, 3f), and slight hypertrophy of the distal tubular epithelium (3m, 1f). In the glandular stomach a slight increase of globule leucocyte in high dose rats (1m, 1f), and slight squamous cell hyperplasia was noted in the proventriculus border in 1 female.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 50 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In rats orally exposed to 0, 50, 250 or 1000 mg/kg bw/day E-BK105 for 28 days followed by a 14-day recovery period (control and high dose only) slight squamous cell hyperplasia at the provericulus border of the stomach was observed at the end of the exposure period in mid and high dose animals, accompanied by an increase of globule leucocytes in the glandular stomach in high dose animals. In kidneys of mid and high dose rats slight hypertrophy of the distal tubular epithelium was observed, together with slight hypertrophy of the collecting tubule epithelium in mid dose males and in high dose males and females. In addition, low plasma sodium values (mid dose females and high dose males and females), low plasma potassium values (high dose females) and low values of plasma chloride (high dose males and females) were noted. At the end of the recovery period, histopathological changes were still present, as wel as decreased plasma sodium and chloride levels . Based on these effects, the NOAEL in this study is set at 50 mg/kg bw/day.
- Executive summary:
E-BK105 was repeatedly administered by oral gavage at dose levels of 0, 50, 250 and 1000 mg/kg bw/day to male and female rats for 28 days to assess the toxicological effects. A 14 -day recovery period was set for the control and high dose group to study reversibility of effects. slight squamous cell hyperplasia at the provericulus border of the stomach was observed in mid and high dose animals, accompanied by an increase of globule leucocytes in the glandular stomach in high dose animals. In kidneys of mid and high dose rats slight hypertrophy of the distal tubular epithelium was observed, together with slight hypertrophy of the collecting tubule epithelium in mid dose males and and in high dose males and females. In addition, low plasma sodium values (mid dose females and high dose males and females), low plasma potassium values (high dose females) and low values of plasma chloride (high dose males and females) were noted. Decreased plasma sodium and chloride levels were still present at the end of the 14-day recovery period. Based on these effects, the NOAEL in this study is set at 50 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)
Vi har mycket webbmaterial på ditt språk, men en del av den här sidan finns bara på engelska. Mer om vår flerspråkighetspolicy finns.
Välkommen till Echas webbplats. Alla funktioner på den här webbplatsen fungerar inte med Internet Explorer 7 (eller tidigare versioner). Det är därför bäst att du uppgraderar till en nyare version.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Läs mer om hur vi använder kakor.